JP2020505440A5 - - Google Patents

Download PDF

Info

Publication number
JP2020505440A5
JP2020505440A5 JP2019557669A JP2019557669A JP2020505440A5 JP 2020505440 A5 JP2020505440 A5 JP 2020505440A5 JP 2019557669 A JP2019557669 A JP 2019557669A JP 2019557669 A JP2019557669 A JP 2019557669A JP 2020505440 A5 JP2020505440 A5 JP 2020505440A5
Authority
JP
Japan
Prior art keywords
group
pharmaceutically acceptable
acceptable salt
compound according
isomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019557669A
Other languages
English (en)
Japanese (ja)
Other versions
JP7237010B2 (ja
JP2020505440A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2018/072088 external-priority patent/WO2018130155A1/zh
Publication of JP2020505440A publication Critical patent/JP2020505440A/ja
Publication of JP2020505440A5 publication Critical patent/JP2020505440A5/ja
Application granted granted Critical
Publication of JP7237010B2 publication Critical patent/JP7237010B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019557669A 2017-01-10 2018-01-10 Hdac6選択的阻害剤およびその製造方法と使用 Active JP7237010B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710017287 2017-01-10
CN201710017287.2 2017-01-10
PCT/CN2018/072088 WO2018130155A1 (zh) 2017-01-10 2018-01-10 Hdac6选择性抑制剂及其制备方法和应用

Publications (3)

Publication Number Publication Date
JP2020505440A JP2020505440A (ja) 2020-02-20
JP2020505440A5 true JP2020505440A5 (enExample) 2021-02-18
JP7237010B2 JP7237010B2 (ja) 2023-03-10

Family

ID=62839715

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019557669A Active JP7237010B2 (ja) 2017-01-10 2018-01-10 Hdac6選択的阻害剤およびその製造方法と使用

Country Status (12)

Country Link
US (1) US10745389B2 (enExample)
EP (1) EP3569592B8 (enExample)
JP (1) JP7237010B2 (enExample)
KR (1) KR102549606B1 (enExample)
CN (1) CN110382463B (enExample)
AU (1) AU2018208160B2 (enExample)
ES (1) ES2927352T3 (enExample)
IL (1) IL267968B (enExample)
MX (1) MX394624B (enExample)
SA (1) SA519402090B1 (enExample)
SG (1) SG11201906361YA (enExample)
WO (1) WO2018130155A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112703190B (zh) * 2018-07-04 2022-08-05 基石药业(苏州)有限公司 Hdac6选择性抑制剂的晶型及其应用
US12485174B2 (en) 2019-06-27 2025-12-02 The George Washington University, A Congressionally Chartered Not-For-Profit Corporation HDAC6-activated macrophages, compositions, and uses thereof
WO2021110121A1 (zh) * 2019-12-05 2021-06-10 基石药业(苏州)有限公司 Hdac6选择性抑制剂及其组合疗法
WO2021127643A1 (en) 2019-12-20 2021-06-24 Tenaya Therapeutics, Inc. Fluoroalkyl-oxadiazoles and uses thereof
MX2023012095A (es) 2021-04-23 2023-12-14 Tenaya Therapeutics Inc Inhibidores de hdac6 para el uso en el tratamiento de la miocardiopatía dilatada.
TW202308619A (zh) 2021-05-04 2023-03-01 美商特納亞治療股份有限公司 用於治療代謝疾病和hfpef的hdac6抑制劑
WO2024123700A1 (en) * 2022-12-05 2024-06-13 The General Hospital Corporation Histone deacetylase inhibitors
WO2025215092A1 (en) 2024-04-10 2025-10-16 Institut National de la Santé et de la Recherche Médicale Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2473505A1 (en) * 2002-02-07 2003-08-14 Ellen M. Leahy Novel bicyclic hydroxamates as inhibitors of histone deacetylase
CN101641338A (zh) * 2006-09-11 2010-02-03 柯瑞斯公司 作为抗增殖制剂的多功能小分子
BRPI0916713A2 (pt) 2008-07-28 2015-11-10 Gilead Science Inc compostos inibidores de histona desacetilase de cicloalquilideno e heterocicloalquilideno
US20110212969A1 (en) * 2010-02-26 2011-09-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
EA025345B1 (ru) * 2010-11-16 2016-12-30 Эситайлон Фармасьютикалз, Инк. Гидроксиамидные соединения пиримидина в качестве ингибиторов деацетилаз белков и фармацевтические композиции для лечения заболевания, обусловленного hdac6, включающие эти соединения
US8404738B2 (en) 2011-01-21 2013-03-26 Hoffmann-La Roche Inc. 4-amino-N-hydroxy-benzamides for the treatment of cancer
EP2826769A1 (en) 2013-07-18 2015-01-21 Institut de Recherche pour le Développement ( IRD) Compounds for the treatment and/or prevention of parasitic diseases and method of production thereof
CA2933907A1 (en) * 2013-12-23 2015-07-02 The Trustees Of Columbia University In The City Of New York Selective hdac6 inhibitors
US9464073B2 (en) * 2014-02-26 2016-10-11 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors

Similar Documents

Publication Publication Date Title
JP2020505440A5 (enExample)
RU2328486C2 (ru) Производные 2-пиридона в качестве ингибиторов нейтрофильной эластазы
JP2012521994A5 (enExample)
JP2016515561A5 (enExample)
CN112533916A (zh) 一种作用于crbn蛋白的三并环类化合物
RU2015133450A (ru) Соединения имидазопиридина и их применение
JP2014506907A5 (enExample)
JP2014507455A5 (enExample)
RU2019104899A (ru) Ингибитор ido1 и способ его получения и применение
JP2007530694A5 (enExample)
JP2020507589A5 (enExample)
CN113365998A (zh) 用于parp抑制剂的吲哚并七元酰肟类似物
CN110382463A (zh) Hdac6选择性抑制剂及其制备方法和应用
JP2014502988A5 (enExample)
JP2014505017A5 (enExample)
CN114072396A (zh) 作为dna-pk抑制剂的喹啉和噌啉衍生物
JP2015516427A5 (enExample)
JP2019535723A5 (enExample)
JP2019516739A5 (enExample)
JP2020511536A5 (enExample)
JP2016503778A5 (enExample)
JP2013518036A5 (enExample)
JP2020519687A5 (enExample)
JP2009040767A5 (enExample)
JP2020504184A5 (enExample)